Decitabine/lutetium-(177Lu)-oxodotreotide/temozolomide: Various toxicities.
In: Reactions Weekly, Jg. 2002 (2024-04-01), Heft 1, S. 158-158
serialPeriodical
Zugriff:
A retrospective review study of 346 patients who received peptide receptor radionuclide therapy (PRRT) found that 14 patients developed myelodysplastic syndrome (MDS), B-cell acute lymphoblastic leukemia (B-ALL), or clonal cytopenia (CC) during treatment with lutetium-(177Lu)-oxodotreotide or temozolomide for neuroendocrine tumors (NET). Three patients also experienced lack of efficacy during treatment with decitabine or lutetium-(177Lu)-oxodotreotide for NET, and one patient developed MDS during off-label treatment with lutetium-(177Lu)-oxodotreotide for pheochromocytoma. The patients received various treatments prior to PRRT, and cytogenetic analysis revealed different mutations. Some patients experienced disease progression and received additional treatments. At the time of the last follow-up, some patients were alive while others had passed away, but the cause of death was not stated. [Extracted from the article]
Titel: |
Decitabine/lutetium-(177Lu)-oxodotreotide/temozolomide: Various toxicities.
|
---|---|
Zeitschrift: | Reactions Weekly, Jg. 2002 (2024-04-01), Heft 1, S. 158-158 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 0114-9954 (print) |
DOI: | 10.1007/s40278-024-55535-y |
Schlagwort: |
|
Sonstiges: |
|